Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | CARs: driving the field forward

Michael Bishop • 26 Oct 2019
COSTEM 2019
Diffuse Large B-Cell Lymphoma Lymphoma CAR-T Checkpoint inhibitors

Michael Bishop, MD, University of Chicago Medical Center, Chicago, IL, discusses the CAR-T research he is most excited about, where the field is likely to move, and the prospect of CAR-T becoming a globally used therapy, replacing more conventional therapies. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Michael Bishop

1:06
Assessing metabolic tumor volume as a prognostic marker before CAR-T therapy for DLBCL
Michael Bishop • 21 Oct 2023
1:10
Tackling resistance to CAR-T therapy across hematological malignancies
Michael Bishop • 21 Oct 2023
1:44
Bispecific antibodies vs CAR-T cells in DLBCL: the benefit of CAR-T therapy
Michael Bishop • 21 Oct 2023
4:38
Current status & progress in CAR-T therapy for hematological malignancies
Michael Bishop • 29 Nov 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals